News
Progress on Lorlatinib – What's Next?
Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell lung cancer (NSCLC) with ALK gene rearrangement. Clinical research is now focusing on the question of how to proceed with patients who experience disease progression during lorlatinib treatment in later lines of therapy. It seems that one of the options might actually be to do nothing – to continue with lorlatinib.
Debate on Sepsis Biomarkers 'on Blood'
Sepsis represents a major cause of death from infectious diseases. Early identification of patients with a prognosis of sepsis is therefore crucial for their survival and prognosis. In addition to…
Current and Future Possibilities for Influencing Immune Thrombocytopenia
The possibilities for treating immune thrombocytopenia (ITP) are quite broad today, with a major advancement for many patients being the advent of thrombopoietin receptor agonists. However, for some…
Romiplostim in a Pregnant Woman − Case Report
The following clinical case demonstrates good control of resistant immune thrombocytopenia in a pregnant woman during the administration of romiplostim.
ID 360 – Immunodeficiency in Interdisciplinary Collaboration 2022
For the second time, a two-day meeting titled "ID 360 – Immunodeficiency in Interdisciplinary Collaboration" took place, this time on March 25–26, 2022, in Prague. Several current topics were…
According to which parameters can we best assess the quality of incontinence aids?
Properly chosen incontinence aid significantly influences the user's quality of life. When selecting incontinence aids, it is very important to consider their individual properties and parameters.…
Correct Selection of Appropriate Incontinence Aid is Crucial for Addressing Patient's Difficulties
Urinary incontinence is an uncomfortable issue that can be resolved by choosing the right incontinence aids. Selecting a quality product is most important for the patient − it affects their comfort…
Experience from Clinical Practice with Intestinal Gel LECIG in Treating Parkinson's Disease
A Swedish observational study evaluated the applicability of the LECIG intestinal gel, which contains levodopa (20 mg/ml), carbidopa (5 mg/ml), and entacapone (20 mg/ml), in clinical practice for…
Eletriptan and Its Role in Acute Migraine Therapy
In the acute treatment of moderate to severe migraine attacks, medications from the triptan group are primarily used. The following article summarizes important findings about eletriptan and its key…
Efficacy and Safety of Bimekizumab in the Treatment of Moderate to Severe Plaque Psoriasis - BE READY Study Results
The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a crucial role in the pathogenesis of psoriasis. Inhibiting interleukins from this family has a…
Current View on the Issue of Protein Intake in Critically Ill Patients
A summary of current knowledge and guidelines concerning the nutritional needs of critically ill patients presented last year in the journal Clinical Nutrition deals with protein intake, specifically…
Reduction of Mortality in Patients After Abdominal Surgery in Critical Condition Thanks to Early Supplemental Parenteral Nutrition
Ensuring adequate nutrition is an important part of therapy for critically ill patients to achieve better clinical outcomes in terms of both survival and recovery speed. The preferred option is…
Empagliflozin Secures Reimbursement for Heart Failure Treatment
Starting May 1st, health insurance companies will cover Jardiance® (empagliflozin) for patients with heart failure with reduced ejection fraction. Cardiologists, pediatric cardiologists,…
Gut-Brain Axis − Future of MS Treatment?
The relationship between the gut microbiome and multiple sclerosis has been a major topic recently. How far has current science progressed in decoding this issue? A recent review article published in…
Teriflunomide under the microscope in studies and practice
Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does this also apply to teriflunomide? Is its efficacy and safety consistent across age groups and…